We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

93 hedge funds and large institutions have $627M invested in Neumora Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 13 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 13

127% more call options, than puts

Call options by funds: $1.81M | Put options by funds: $797K

26% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 19

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

6.85% more ownership

Funds ownership: 33.17% → 40.01% (+6.8%)

6% more funds holding

Funds holding: 88 → 93 (+5)

14% less capital invested

Capital invested by funds: $725M → $627M (-$98M)

Holders
93
Holders Change
+5
Holders Change %
+5.68%
% of All Funds
1.34%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
24
Increased
42
Reduced
13
Closed
19
Calls
$1.81M
Puts
$797K
Net Calls
+$1.01M
Net Calls Change
+$1.39M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$37.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$30.4M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$15.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.8M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.62M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$10.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$9.97M
3
SCM
Soros Capital Management
New York
-$4.09M
4
PC
Pier Capital
Connecticut
-$3.43M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
AH
26
Addis & Hill
Pennsylvania
$2.94M -$153K -14,821 -5%
Voloridge Investment Management
27
Voloridge Investment Management
Florida
$2.91M +$3.06M +295,973 New
UBS Group
28
UBS Group
Switzerland
$2.91M +$2.8M +270,376 +1,069%
Charles Schwab
29
Charles Schwab
California
$2.86M +$1.73M +166,822 +134%
AllianceBernstein
30
AllianceBernstein
Tennessee
$2.63M +$2.76M +267,225 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.32M +$2.01M +194,559 +474%
SSA
32
Schonfeld Strategic Advisors
New York
$2.23M -$228K -22,010 -9%
N
33
Nuveen
North Carolina
$2.22M +$2.12M +204,983 +988%
Two Sigma Investments
34
Two Sigma Investments
New York
$1.7M +$1.78M +172,520 New
KCM
35
Kennedy Capital Management
Missouri
$1.66M +$330K +31,858 +23%
WP
36
Woodline Partners
California
$1.61M +$1.7M +164,160 New
Morgan Stanley
37
Morgan Stanley
New York
$1.54M +$945K +91,363 +140%
Ensign Peak Advisors
38
Ensign Peak Advisors
Utah
$1.47M – – –
TD Asset Management
39
TD Asset Management
Ontario, Canada
$1.43M +$360K +34,800 +32%
Northern Trust
40
Northern Trust
Illinois
$1.37M +$189K +18,246 +15%
Marshall Wace
41
Marshall Wace
United Kingdom
$1.32M +$1.39M +134,545 New
AA
42
ALPS Advisors
Colorado
$1.22M +$173K +16,709 +16%
WC
43
Wexford Capital
Florida
$1.13M +$884K +85,421 +293%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.1M +$512K +49,527 +79%
Norges Bank
45
Norges Bank
Norway
$1.08M – – –
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$1.02M +$887K +85,706 +488%
Franklin Resources
47
Franklin Resources
California
$864K +$910K +87,943 New
IC
48
IEQ Capital
California
$814K – – –
AGM
49
Alpine Global Management
New York
$646K +$680K +65,728 New
JP Morgan Chase
50
JP Morgan Chase
New York
$617K +$291K +28,081 +81%
1
2
3 4 5

NMRA Hedge Fund Activity: Q2 2024 in Review

93 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2024, worth a combined $627M — down 14% from $725M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new NMRA positions and 19 closed out — a net gain of 5 holders — while 42 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $37.4M. The largest seller was Deep Track Capital, exiting entirely with an estimated $10.3M sold.

  • 93 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2024, up from 88 in Q1 2024.
  • Funds reported $627M of Neumora Therapeutics stock for Q2 2024, down 14% quarter-over-quarter.
  • 24 funds opened new Neumora Therapeutics positions in Q2 2024 and 19 closed out, a net change of +5 holders.
  • The largest Neumora Therapeutics buyer in Q2 2024 was BlackRock, an estimated $37.4M added.
  • The largest Neumora Therapeutics seller in Q2 2024 was Deep Track Capital, an estimated $10.3M sold.

Based on aggregated 13F filings for Q2 2024.